EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access

Disitamab Vedotin in HER2-Positive and HER2-Low Breast Cancer: A Multicenter Retrospective Analysis

Xizhou Zhang, Zetao Zhang, Jianguang Lin, Jiarong Yi, Xuxiazi Zou, Jikun Feng, Guangsheng Huang, Bingfeng Chen, Junxi Long, Fengjia Wu, Feng Ye, Haoming Wu

Oncology Research · 2025 · 33 (9) · 2529-2547

DOI: 10.32604/or.2025.065029 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Oncology Research, 2025. Verfasst von Xizhou Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: The Breast Center, Cancer Hospital of Shantou University Medical College, Guangdong Provincial Key Laboratory of Breast Cancer Diagnosis and Treatmen…. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Immunoconjugates. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesImmunoconjugatesHumansFemaleRetrospective StudiesMiddle AgedAgedAdultAged, 80 and overProgression-Free SurvivalAntibodies, MonoclonalOligopeptides

Stichwörter der Autor:innen

ADCDisitamab vedotinHER2-RC48HER2-lowantibody-drug conjugatesbreast cancerreal-world study

Substanzen

Erb-b2 Receptor Tyrosine KinasesImmunoconjugatesAntibodies, MonoclonalOligopeptidesERBB2 protein, humandisitamab vedotin

Autor:innen und Institutionen

  • The Breast Center, Cancer Hospital of Shantou University Medical College, Guangdong Provincial Key Laboratory of Breast Cancer Diagnosis and Treatment, Shantou, 515031, China.
  • Department of Oncology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, 362000, China.
  • State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.

Zitieren

APA

Zhang, X., Zhang, Z., Lin, J., Yi, J., Zou, X., Feng, J., Huang, G., Chen, B., Long, J., Wu, F., Ye, F., & Wu, H. (2025). Disitamab Vedotin in HER2-Positive and HER2-Low Breast Cancer: A Multicenter Retrospective Analysis. Oncology Research, 33(9), 2529-2547. https://doi.org/10.32604/or.2025.065029

Vancouver

Zhang X, Zhang Z, Lin J, Yi J, Zou X, Feng J, et al. Disitamab Vedotin in HER2-Positive and HER2-Low Breast Cancer: A Multicenter Retrospective Analysis. Oncology Research. 2025;33(9):2529-2547. doi:10.32604/or.2025.065029

BibTeX
@article{Zhang2025,
  author = {Zhang, Xizhou and Zhang, Zetao and Lin, Jianguang and Yi, Jiarong and Zou, Xuxiazi and Feng, Jikun and Huang, Guangsheng and Chen, Bingfeng and Long, Junxi and Wu, Fengjia and Ye, Feng and Wu, Haoming},
  title = {Disitamab Vedotin in HER2-Positive and HER2-Low Breast Cancer: A Multicenter Retrospective Analysis},
  journal = {Oncology Research},
  year = {2025},
  volume = {33},
  number = {9},
  pages = {2529--2547},
  doi = {10.32604/or.2025.065029}
}
Kostenlos starten →